➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Harvard Business School
Medtronic
Johnson and Johnson
Baxter

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ganetespib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Ganetespib?

Ganetespib is an investigational drug.

There have been 31 clinical trials for Ganetespib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., Dana-Farber Cancer Institute, and Emory University.

There are five hundred and twenty-five US patents protecting this investigational drug and five international patents.

Recent Clinical Trials for Ganetespib
TitleSponsorPhase
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerEuropean CommissionPhase 2
European Trial on Enhanced DNA Repair Inhibition in Ovarian CancerUniversitaire Ziekenhuizen LeuvenPhase 2
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast CancerUniversity of ChicagoN/A

See all Ganetespib clinical trials

Clinical Trial Summary for Ganetespib

Top disease conditions for Ganetespib
Top clinical trial sponsors for Ganetespib

See all Ganetespib clinical trials

US Patents for Ganetespib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganetespib   Get Started Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
Ganetespib   Get Started Free Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Get Started Free
Ganetespib   Get Started Free Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE)   Get Started Free
Ganetespib   Get Started Free Bicyclic bromodomain inhibitors Zenith Epigenetics Ltd. (Calgary, AB, CA)   Get Started Free
Ganetespib   Get Started Free Small molecule HSP70 inhibitors The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA)   Get Started Free
Ganetespib   Get Started Free Glutaminase inhibitors and method of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
Ganetespib   Get Started Free Constructs targeting AFP peptide/MHC complexes and uses thereof EUREKA THERAPEUTICS, INC. (Emeryville, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganetespib

Drugname Country Document Number Estimated Expiration Related US Patent
Ganetespib Australia AU2015231053 2034-03-21   Get Started Free
Ganetespib Brazil BR112016021620 2034-03-21   Get Started Free
Ganetespib Canada CA2943339 2034-03-21   Get Started Free
Ganetespib China CN106231900 2034-03-21   Get Started Free
Ganetespib Eurasian Patent Organization EA201691896 2034-03-21   Get Started Free
Ganetespib European Patent Office EP3119199 2034-03-21   Get Started Free
Ganetespib Israel IL247921 2034-03-21   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
AstraZeneca
Express Scripts
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.